Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study

por Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Al-Buhadily, Ali K.
Publicado 2018

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors

por Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Al-Niemi, Marwa S., Al-Buhadily, Ali K., Al-Harchan, Nasser A., Lugnier, Claire
Publicado 2020

The Potential Role of Pancreatic γ-Aminobutyric Acid (GABA) in Diabetes Mellitus: A Critical Reappraisal

por Al-Kuraishy, Hayder M., Hussian, Nawar R., Al-Naimi, Marwa S., Al-Gareeb, Ali I., Al-Mamorri, Farah, Al-Buhadily, Ali K.
Publicado 2021

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

por Alomair, Basil Mohammed, Al-kuraishy, Hayder M., Al-Buhadily, Ali K., Al-Gareeb, Ali I., De Waard, Michel, Elekhnawy, Engy, Batiha, Gaber El-Saber
Publicado 2022

Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship

por Batiha, Gaber El-Saber, Al-kuraishy, Hayder M., Al-Maiahy, Thabat J., Al-Buhadily, Ali K., Saad, Hebatallah M., Al-Gareeb, Ali I., Simal-Gandara, Jesus
Publicado 2022

Citicoline and COVID-19: vis-à-vis conjectured

por Al-kuraishy, Hayder M., Al-Buhadily, Ali K., Al-Gareeb, Ali I., Alorabi, Mohammed, Hadi Al-Harcan, Nasser A., El-Bouseary, Maisra M., Batiha, Gaber El-Saber
Publicado 2022

Mixed storm in SARS‐CoV‐2 infection: A narrative review and new term in the Covid‐19 era

por Alomair, Basil Mohammed, Al‐Kuraishy, Hayder M., Al‐Gareeb, Ali I., Al‐Buhadily, Ali K., Alexiou, Athanasios, Papadakis, Marios, Alshammari, Majed Ayed, Saad, Hebatallah M., Batiha, Gaber El‐Saber
Publicado 2023

SARS‐CoV‐2 induced HDL dysfunction may affect the host's response to and recovery from COVID‐19

por Al‐kuraishy, Hayder M., Hussien, Nawar R., Al‐Niemi, Marwa S., Fahad, Esraa H., Al‐Buhadily, Ali K., Al‐Gareeb, Ali I., Al‐Hamash, Sadiq M., Tsagkaris, Christos, Papadakis, Marios, Alexiou, Athanasios, Batiha, Gaber El‐Saber
Publicado 2023